Building on its widely used models in Alzheimer’s Disease (AD), Evidera scientists designed the AD ACE to assess interventions that may cover from the earliest (i.e., mild cognitive impairment or prodromal AD) through the most severe stages of the disease, as well as the transition from normal cognitive function. ACE simulators are comprehensive, extensively documented, multi-application disease-specific models designed to support commercial strategy development, inform clinical trial designs, and meet HTA agency requirements for formal submissions. The AD ACE addresses the complex interactions between multiple components of AD pathology (e.g., biomarkers, cognition, behavior, function) and their role in disease progression. It also fully considers interrelated clinical, epidemiologic and economic outcomes, providing a platform that allows for rapid incorporation of intervention-specific data.
As the AD ACE is programmed in MS Excel®, it does not require any additional software and it is very transparent, a key feature for HTA bodies, decision makers, and internal stakeholders. In addition, it is readily modified to address the specific features of the therapy or diagnostic that’s being studied.